Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T, Rosta A, Losonczy H, Radványi G, Ujj G, Egyed M, Illés Á, Jakucs J, Szerafin L, Gasztonyi Z, Masszi T, Iványi J, Demeter J, Dombi P, Tóth A, Borbényi Z. Schneider T, et al. Among authors: masszi t. Pathol Oncol Res. 2018 Apr;24(2):199-205. doi: 10.1007/s12253-017-0234-2. Epub 2017 Apr 21. Pathol Oncol Res. 2018. PMID: 28432650 Free article. Clinical Trial.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. Harousseau JL, et al. Among authors: masszi t. Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21. Blood. 2009. PMID: 19470696 Free article. Clinical Trial.
Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population.
Mohl A, Boda Z, Jager R, Losonczy H, Marosi A, Masszi T, Nagy E, Nemes L, Obser T, Oyen F, Radványi G, Schlammadinger Á, Szélessy ZS, Várkonyi A, Vezendy K, Vilimi B, Schneppenheim R, Bodó I. Mohl A, et al. Among authors: masszi t. J Thromb Haemost. 2011 May;9(5):945-52. doi: 10.1111/j.1538-7836.2011.04250.x. J Thromb Haemost. 2011. PMID: 21362127 Free article.
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H. Meggyesi N, et al. Among authors: masszi t. Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14. Acta Haematol. 2012. PMID: 22005133
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Stone RM, et al. Among authors: masszi t. J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2. J Clin Oncol. 2015. PMID: 25732165 Clinical Trial.
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. Hájek R, et al. Among authors: masszi t. Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24. Leukemia. 2017. PMID: 27416912 Free PMC article. Clinical Trial.
[Chronic myelogenous leukemia: diagnosis and treatment].
Demeter J, Poros A, Bödör C, Horváth L, Masszi T. Demeter J, et al. Among authors: masszi t. Orv Hetil. 2016 Sep;157(37):1459-68. doi: 10.1556/650.2016.30521. Orv Hetil. 2016. PMID: 27615196 Hungarian.
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É, Egyed M, Pál K, Radványi G, Hamed A, Csomor J, Matolcsy A, Alpár D, Bödör C. Gángó A, et al. Among authors: masszi t. Leuk Res. 2018 Feb;65:42-48. doi: 10.1016/j.leukres.2017.12.005. Epub 2018 Jan 2. Leuk Res. 2018. PMID: 29306106
[Systemic mastocytosis with progressive disease course].
Várkonyi J, Szombath G, Vályi-Nagy A, Csomor J, Egedi K, Kovalszky I, Tölgyesi K, Szerafin L, Tóth L, Soós G, Masszi T. Várkonyi J, et al. Among authors: masszi t. Orv Hetil. 2018 Feb;159(5):192-196. doi: 10.1556/650.2018.30978. Orv Hetil. 2018. PMID: 29376426 Hungarian.
199 results